{"id":4466,"date":"2025-03-31T18:12:09","date_gmt":"2025-03-31T18:12:09","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/vigabatrin-txt\/"},"modified":"2025-03-31T18:12:09","modified_gmt":"2025-03-31T18:12:09","slug":"vigabatrin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/vigabatrin-txt\/","title":{"rendered":"Vigabatrin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3> Anti-epileptic agent

DOSE IN NORMAL RENAL FUNCTION <\/H3> 1\u20133 g daily in single or divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : 129.2 <\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Negligible <\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 60\u201380 <\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp : 0.8 <\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp : 5\u20138\/13\u201315

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Give 50% of normal dose and titrate to response
  • 10 to 20 &nbsp &nbsp : Give 50% of normal dose and titrate to response
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Give 25% of normal dose and titrate to response

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp: Unknown dialysability. Dose as for GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : Dialysed. Dose as for GFR <10 mL\/min
  • HDF\/high flux &nbsp : Dialysed. Dose as for GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp: Unknown dialysability. Dose as for GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3> Potentially hazardous interactions with other drugs\n
  • Antidepressants: anticonvulsant effect antagonised, convulsive threshold lowered\n
  • Anti-epileptics: concentration of phenytoin and possibly phenobarbital and primidone reduced\n
  • Antimalarials: mefloquine antagonises anticonvulsant effect; chloroquine and hydroxychloroquine occasionally reduce convulsive threshold

    ADMINISTRATION <\/H3>

    Reconstition<\/H4> \u2013

    Route <\/H4> Oral

    Rate of Administration <\/H4> \u2013

    Comments<\/H4> \u2013 .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Anti-epileptic agent DOSE IN NORMAL RENAL FUNCTION 1\u20133<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4466","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4466","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4466"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4466\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4466"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4466"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4466"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}